Compounds of the formula ##STR00001## and pharmaceuticaly acceptable salts thereof, wherein Q.sup.1 and R.sup.1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.